Antifactor Xa levels in four patients with burn injuries who received enoxaparin to prevent venous thromboembolism

Pharmacotherapy

Volumn 24, Issue 12 I, 2004, Pages 1793-1799

  Yogaratnam, Dinesh ^a   Smith, Brian S ^b   Angood, Peter B ^b,c   Gandhi, Pritesh J ^d  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b Univ of MA   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Antifactor Xa level; Burns; Deep vein thrombosis; Enoxaparin; Low molecular weight heparin; Thermal injury

Indexed keywords

AMIKACIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN; HEPARIN;

ADULT; ARTICLE; BLEEDING; BURN; CASE REPORT; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; ECHOGRAPHY; FEMALE; HUMAN; MALE; MEDICAL RECORD; PROPHYLAXIS; QUANTITATIVE ANALYSIS; VENOUS THROMBOEMBOLISM; WOUND INFECTION;

ADULT; ANTITHROMBIN III; BURNS; ENOXAPARIN; FEMALE; HUMANS; MALE; VENOUS THROMBOSIS;

EID: 9644273906     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.17.1793.52344     Document Type: Article

References (25)

1. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001;119:132S-75.
2. Wahl WL, Brandt MM, Ahrns KS, et al. Venous thrombosis incidence in burn patients: preliminary results of a prospective study. J Burn Care Rehabil 2002;23:97-102.
3. Orr PA, Case KO, Stevenson JJ. Metabolic response and parenteral nutrition in trauma, sepsis, and burns. J Infus Nurs 2002;25:45-53.
4. Ahrns KS, Harkins DR. Initial resuscitation after burn injury: therapies, strategies, and controversies. Am Assoc Crit Care Nurses Clin Issues 1999;10:46-60.
5. Nguyen TT, Gilpin DA, Meyer NA, Herndon DN. Current treatment of severely burned patients. Ann Surg 1996;223:14-25.
6. Jaehde U, Sorgel F. Clinical pharmacokinetics in patients with burns. Clin Pharmacokinet 1995;29:15-28.
7. Weinbren MJ. Pharmacokinetics of antibiotics in burn patients. J Antimicrob Chemother 1999;44:319-27.
8. Aventis Pharmaceuticals Inc. Lovenox (enoxaparin) package insert. Bridgewater, NJ; 2004.
9. Gerlach AT, Pickworth KK, Seth SK, Tanna SB, Barnes JF. Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy 2000;20:771-5.
10. Lott RS, Uden DL, Wargin WA, Strate RG, Zaske DE. Correlation of predicted versus measured creatinine clearance values in burn patients. Am J Hosp Pharm 1978;35:717-20.
11. Kovacs MJ, Weir K, MacKinnon K, Keeney M, Brien WF, Cruickshank MK. Body weight does not predict for anti-Xa levels after fixed dose prophylaxis with enoxaparin after orthopedic surgery. Thromb Res 1998;91:137-42.
12. Bara L, Leizorovicz A, Picolet H, Samama M. Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in post-surgical patients treated with either Logiparin (LMWH) or unfractionated heparin. Post-surgery Logiparin study group. Thromb Res 1992;65:641-50.
13. Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M. The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost 1989;62:940-4.
14. Bara L, Planes A, Samama MM. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery. Br J Haematol 1999;104:230-40.
15. Mayr AJ, Dunser M, Jochberger S, et al. Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin. Thromb Res 2002;105:201-4.
16. Priglinger U, Delle Karth G, Geppert A, et al. Prophylactic anticoagulation with enoxaparin: is the subcutaneous route appropriate in the critically ill? Crit Care Med 2003;31:1405-9.
17. Dorffler-Melly J, de Jonge E, Pont AC, et al. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 2002;359:849-50.
18. Frederiksen SG, Hedenbro JL, Norgren L. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J Surg 2003;90:547-8.
19. Kroon C, de Boer A, Kroon JM, et al. Influence of skinfold thickness on heparin absorption. Lancet 1991;337:945-6.
20. Dechavanne M, Ville D, Berruyer M, et al. Randomized trial of a low-molecular-weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery. Haemostasis 1989;19:5-12.
21. Taberner DA, Poller L, Thomson JM, Lemon G, Weighill FJ. Randomized study of adjusted versus fixed low dose heparin prophylaxis of deep vein thrombosis in hip surgery. Br J Surg 1989;76:933-5.
22. Leyvraz PF, Richard J, Bachmann F, et al. Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 1983;309:954-8.
23. Ellis RJ, Cunningham MT, Cook JD. Laboratory heparin resistance in burn injury complicated by venous thrombosis. Burns 1999;25:749-52.
24. Shepherd MF, Rosborough TK, Schwartz ML. Heparin thromboprophylaxis in gastric bypass surgery. Obes Surg 2003;13:249-53.
25. Fareed J, Hoppensteadt D, Walenga J, et al. Pharmacodynamic and pharmacokinetic properties of enoxaparin: implications for clinical practice. Clin Pharmacokinet 2003;42:1043-57.